

Randomised, double-blind, controlled study of the tranexamic acid prophylaxis efficacy on the development of systemic inflammatory response syndrome and postoperative bleeding in cardiopulmonary bypass surgery patients

Submission date 21/03/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 18/05/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 05/01/2021	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Jose Luis Iribarren

Contact details
Ofra s/n
La Laguna
Spain
38320

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Randomised, double-blind, controlled study of the tranexamic acid prophylaxis efficacy on the development of systemic inflammatory response syndrome and postoperative bleeding in cardiopulmonary bypass surgery patients

Acronym

TX/02

Study objectives

We hypothesised that the inhibition of fibrinolysis through the administration of tranexamic acid could reduce the incidence of systemic inflammatory response syndrome and postoperative bleeding after cardiopulmonary bypass.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the University Hospital of Canary Islands Ethics and Research Council on the 20th December 2001 (ref: 35/01).

Study design

Randomised, double-blind, controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Systemic inflammatory response syndrome

Interventions

Infusions of either tranexamic acid or placebo (0.9% saline), with doses of 2 g pre- and post-cardiopulmonary bypass after protamine administration.

Follow-up continued until the patient was discharged from the hospital.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Tranexamic acid, protamine

Primary outcome measure

To investigate the efficacy of tranexamic acid in decreasing the incidence of systemic inflammatory response syndrome and postoperative bleeding.

Data was recorded preoperatively, after surgery, at Intensive Care Unit admission (0 hours), four hours and 24 hours.

Secondary outcome measures

To investigate the efficacy of tranexamic acid to reduce excessive postoperative bleeding in patients undergoing cardiac surgery, according to the presence of different genotypes of the Plasminogen Activator Inhibitor (PAI-1) gene.

Data was recorded preoperatively, after surgery, at Intensive Care Unit admission (0 hours), four hours and 24 hours.

Overall study start date

01/06/2002

Completion date

01/09/2003

Eligibility**Key inclusion criteria**

Consecutive Caucasian adults undergoing elective cardiopulmonary bypass surgery with normal aggregation and coagulation test values.

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

100

Total final enrolment

50

Key exclusion criteria

1. Emergency interventions
2. Patients with a history of haemostatic dysfunction
3. Renal failure (creatinine greater than 2 mg/dl)
4. Chronic hepatopathy
5. Immunodepressed patients
6. Sepsis

Date of first enrolment

01/06/2002

Date of final enrolment

01/09/2003

Locations**Countries of recruitment**

Spain

Study participating centre

Ofra s/n

La Laguna

Spain

38320

Sponsor information**Organisation**

University Hospital of Canary Islands (Consortio Sanitario de Tenerife [CST]) (Spain)

Sponsor details

c/o Juan José Jiménez Rivera

Ofra s/n

La Laguna

Spain

38320

Sponsor type

Hospital/treatment centre

Website

<http://www.hecit.es/index.html>

ROR

<https://ror.org/05qndj312>

Funder(s)

Funder type

Research organisation

Funder Name

Canary Islands Foundation of Health Research (Fundación Canaria de Investigación y Salud [FUNCIS]) (Spain) (ref: 2202)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2007	05/01/2021	Yes	No